Evidence map›Paper›PMID 41307158›Full record

ArticleHead & neck2026

Postoperative Adjuvant Therapy in Resectable Advanced Oral Squamous Cell Carcinoma With Intermediate Risk Factors.

Koichi Koizumi, Fumitaka Obayashi, Mirai Higaki, Kota Morishita, Atsuko Hamada, Sachiko Yamasaki, Nanako Ito, Souichi Yanamoto

Abstract read
In one paragraph

Article in Head & neck, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Koichi KoizumiDepartment of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Fumitaka ObayashiDepartment of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID 0000-0001-6427-6354
Mirai HigakiDepartment of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Kota MorishitaDepartment of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Atsuko HamadaDepartment of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Sachiko YamasakiDepartment of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID 0000-0003-0390-7014
Nanako ItoDepartment of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID 0000-0002-1933-7274
Souichi YanamotoDepartment of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.ORCID 0000-0003-2372-8347

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPostoperative adjuvant therapy strategies are generally determined based on pathological risk stratification in oral cancer. However, the efficacy of postoperative adjuvant therapy in patients with intermediate-risk factors for recurrence of oral cancer such as close surgical margins, pT3-T4 classification, pN2-N3 nodal status, perineural invasion, vascular invasion, lymphatic invasion and pattern of invasion remains unclear, and no standardized treatment guidelines or consensus have been established to date. Therefore, this study retrospectively analyzed the clinical significance of risk factors for pathological recurrence in patients with advanced oral cancer and evaluated the impact of postoperative adjuvant therapy on patient prognosis.

methodsThis retrospective clinical study included 130 patients who underwent initial radical surgical resection for advanced oral squamous cell carcinoma (OSCC) at our institution between January 2010 and December 2023. The postoperative recurrence risk factors included ENE of the cervical lymph nodes, positive surgical margins, close surgical margins, pathological T classification (pT3 or pT4), pathological N classification (pN2 or pN3), metastasis to level IV or V lymph nodes, perineural invasion, vascular invasion, and lymphatic invasion. We analyzed the relationships among the presence of these risk factors, administration of postoperative adjuvant therapy (RT or CRT), occurrence of recurrence or metastasis, and patient prognosis (DFS).

resultsPatients with lymphatic invasion had a significantly lower survival rate than those without lymphatic invasion (66.7% vs. 82.8%, p < 0.05). Although pT4, pN2-N3, perineural invasion-positive and vascular invasion-positive did not reach statistical significance, a trend toward reduced survival was observed in each case. The perineural invasion-positive group had significantly higher recurrence and metastasis rates than the perineural invasion-negative group (51.9% vs. 23.6%, p < 0.05). Multivariate analysis using logistic regression also confirmed the presence of perineural invasion as an independent prognostic factor (HR = 4.496, p = 0.019).

conclusionsThis study demonstrated that perineural invasion is a significant risk factor for recurrence and that lymphatic invasion is a poor prognostic factor in oral cancer. Postoperative adjuvant therapy in patients with perineural or lymphatic invasion-positive disease contributed to reduced recurrence rates and prolonged survival. These findings suggest that the pathological evaluation of perineural and lymphatic invasions is an important indicator in determining the appropriateness of postoperative adjuvant therapy.

Indexed as

Carcinoma, Squamous CellMouth NeoplasmsNeoplasm Recurrence, LocalAdultAgedAged, 80 and overChemoradiotherapy, AdjuvantChemotherapy, AdjuvantFemaleHumansLymphatic MetastasisMaleMargins of ExcisionMiddle AgedNeoplasm InvasivenessNeoplasm Stagingchemoradiotherapy (CRT)intermediate risk factorpostoperative adjuvant therapyradiotherapy (RT)resectable advanced OSCC

Identifiers

PMID41307158
PMCPMC12972644

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.